Protein phosphatase 2 phosphatase activator (PTPA) promotes oncogene-induced senescence and carboplatin response in human malignant pleural mesothelioma cells.

ABSTRACT:

Purpose

Malignant pleural mesothelioma (MPM) is a rare cancer of the pleura, frequently related to asbestos exposure. It is characterized by a grim prognosis, as few therapeutic options are available. Typically, MPM exhibits high molecular heterogeneity, providing opportunities for exploiting therapeutic vulnerabilities in well-defined subgroups of patients. Nevertheless, these options have been insufficiently explored.

Methods & results

We found that inactivation of Protein Phosphatase 2A (PP2A) is a recurrent event in MPM, affecting the cancer cell phenotype and chemotherapy response. Specifically, in silico analysis showed that heterozygous loss of PTPA (PPP2R4), encoding the PP2A activator PTPA, occurred in 26% of MPM patients (TCGA, n = 87), correlating with significant

SUBMITTER: Nigliato E 

PROVIDER: S-EPMC13473063 | biostudies-literature | 2026 Jun

REPOSITORIES: biostudies-literature